{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:30Z","timestamp":1786977330033,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T00:00:00Z","timestamp":1131494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The response of cyclosporine A (CyA) blood concentrations following changes in lipoprotein levels have been inconsistent. Some studies show increases in concentrations, whereas others have shown decreases. The intent of this study was to examine the effect of two rat models of increased lipoprotein on the pharmacokinetics of CyA. One was a simulated high fat content meal, in which 1% cholesterol in peanut oil was administered. The other was the poloxamer 407\u2010induced model of hyperlipidemia. Rats in these two groups were compared to a group fasted overnight before the study. In rats given a simulated high fat meal, at most time points the mean blood and plasma concentrations were lower, though not significantly, compared to fasted animals. Oral lipid led to no significant changes in the measured pharmacokinetic parameters of blood or plasma area under the concentration vs time curve (\n                    <jats:italic>AUC<\/jats:italic>\n                    ), clearance (\n                    <jats:italic>CL<\/jats:italic>\n                    ), volume of distribution (\n                    <jats:italic>Vd<\/jats:italic>\n                    ) or plasma unbound fraction. In the poloxamer 407\u2010treated hyperlipidemic rats there were significant reductions in plasma unbound fraction plasma,\n                    <jats:italic>Vd<\/jats:italic>\n                    and terminal half\u2010life, but not\n                    <jats:italic>AUC<\/jats:italic>\n                    or\n                    <jats:italic>CL<\/jats:italic>\n                    , compared to normolipidemic rats. In contrast, the\n                    <jats:italic>CL<\/jats:italic>\n                    ,\n                    <jats:italic>Vd<\/jats:italic>\n                    and\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    in the oral lipid\u2010fed rats were all significantly higher than the poloxamer 407 treated animals. Oral absolute bioavailability of CyA was unchanged by oral lipid. In humans and rats the pharmacokinetics of CyA in the face of increased lipoprotein levels do not correspond well to what is typically seen for other drugs that are known to bind to lipoproteins. Copyright \u00a9 2005 John Wiley &amp; Sons, Ltd.\n                  <\/jats:p>","DOI":"10.1002\/bdd.476","type":"journal-article","created":{"date-parts":[[2005,11,16]],"date-time":"2005-11-16T16:20:27Z","timestamp":1132158027000},"page":"7-16","source":"Crossref","is-referenced-by-count":40,"title":["The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat"],"prefix":"10.1002","volume":"27","author":[{"given":"Dion R.","family":"Brocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Ala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza Montazeri","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,11,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(01)00151-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/js9704846"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10182"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.457"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90643-W"},{"key":"e_1_2_1_7_2","first-page":"339","article-title":"Cyclosporine disposition in the hyperlipidemic rat model","volume":"59","author":"Brunner LJ","year":"1988","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510120607"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199901150-00008"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.683"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199308000-00003"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03324.x"},{"key":"e_1_2_1_13_2","first-page":"50","article-title":"Is the plasma lipoprotein level of importance for treatment with cyclosporine?","volume":"18","author":"Lithell H","year":"1986","journal-title":"Transplant Proc"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199405270-00014"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015831408425"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90668-M"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/js9704846"},{"key":"e_1_2_1_18_2","first-page":"305","article-title":"Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat","volume":"253","author":"Urien S","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6017(200008)89:8<1008::AID-JPS5>3.0.CO;2-B"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00062-4"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(97)00008-3"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0090-9556(24)15104-5","article-title":"Dose\u2010dependent pharmacokinetics of cyclosporin A in rats: events in tissues","volume":"28","author":"Tanaka C","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb01868.x"},{"key":"e_1_2_1_25_2","first-page":"189","article-title":"Poloxamer 407\u2010mediated alterations in the activities of enzymes regulating lipid metabolism in rats","volume":"6","author":"Wasan KM","year":"2003","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_2_1_26_2","first-page":"547","article-title":"Effects of low\u2010density lipoprotein and ethinyl estradiol on cyclosporine metabolism in isolated rat liver perfusions","volume":"20","author":"Prueksaritanont T","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199912000-00010"},{"key":"e_1_2_1_28_2","first-page":"809","volume-title":"Tietz Textbook of Clinical Chemistry","author":"Rifal N","year":"1999"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1982.tb06206.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.476","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T12:49:24Z","timestamp":1736081364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1002\/bdd.476"],"URL":"https:\/\/doi.org\/10.1002\/bdd.476","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,9]]}}}